中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
1期
123-124
,共2页
舒利迭%慢性阻塞性肺疾病%噻托溴胺%肺功能
舒利迭%慢性阻塞性肺疾病%噻託溴胺%肺功能
서리질%만성조새성폐질병%새탁추알%폐공능
Seretide%COPD%Tiotropium%Lung function
目的：探讨舒利迭联合噻托溴胺吸入治疗慢性阻塞性肺疾病的临床疗效。方法：将110例患者随机分为对照组53例和观察组57例。除常规治疗外,对照组给予舒利迭2次/d,观察组额外给予噻托溴胺1次/d,治疗12周。于治疗前后分别测定肺功能FEV1(L)、FEV1(%)、FEV1/FVC(%)。结果：经治疗后两组患者肺功能均有显著改善(P<0.05)。观察组肺功能指标明显高于对照组(P<0.05),结论：舒利迭与噻托溴胺联合使用治疗慢性阻塞性肺疾病疗效良好,可显著改善肺功能,不良反应较小,效果优于单用舒利迭。
目的：探討舒利迭聯閤噻託溴胺吸入治療慢性阻塞性肺疾病的臨床療效。方法：將110例患者隨機分為對照組53例和觀察組57例。除常規治療外,對照組給予舒利迭2次/d,觀察組額外給予噻託溴胺1次/d,治療12週。于治療前後分彆測定肺功能FEV1(L)、FEV1(%)、FEV1/FVC(%)。結果：經治療後兩組患者肺功能均有顯著改善(P<0.05)。觀察組肺功能指標明顯高于對照組(P<0.05),結論：舒利迭與噻託溴胺聯閤使用治療慢性阻塞性肺疾病療效良好,可顯著改善肺功能,不良反應較小,效果優于單用舒利迭。
목적：탐토서리질연합새탁추알흡입치료만성조새성폐질병적림상료효。방법：장110례환자수궤분위대조조53례화관찰조57례。제상규치료외,대조조급여서리질2차/d,관찰조액외급여새탁추알1차/d,치료12주。우치료전후분별측정폐공능FEV1(L)、FEV1(%)、FEV1/FVC(%)。결과：경치료후량조환자폐공능균유현저개선(P<0.05)。관찰조폐공능지표명현고우대조조(P<0.05),결론：서리질여새탁추알연합사용치료만성조새성폐질병료효량호,가현저개선폐공능,불량반응교소,효과우우단용서리질。
Objective:To observe the effect of Seretide and tiotropium in the treatment of chronic obstructive pulmonary disease (COPD).Methods:120 patients were randomly divided into observation group with 57 cases and control group with 53 cases, both groups were given conventional therapy.The control group was given Seretide twice a day, the observation group was given Seretide twice a day and tiotropium once a day.Two groups were treated for 12 weeks. Pulmonary function FEV1(L),FEV1(%)and FEV1/FVC(%) of two groups were detected before and after treatment.Results:Two groups with chronic obstructive pulmonary disease significantly improve after treatment(P<0.05);Compared with the control group after treatment, lung function index of the observation group increased significantly(P<0.05).Conclusion:Serefide and tiotropium can improve lung function of the parents with COPD obvious,curative effect is better than serefide.
